- The company announced it's developing a new category of
consumer biowearables called Lingo, which is being designed to
track key signals in the body – such as glucose, ketones, and
lactate – to help people better understand their general health and
- Abbott is the first
healthcare company to headline the Consumer Electronics Show, with
Chairman and CEO Robert Ford
presenting alongside scientists and inventors, industry partners,
influencers and people who use Abbott health tech
LAS VEGAS, Jan. 6, 2022 /PRNewswire/ -- Making CES history,
Abbott (NYSE: ABT) presented a
keynote at the most influential tech event in the world, the first
healthcare company ever to do so.
Abbott Chairman and Chief Executive Officer Robert B. Ford headlined the event,
"Human-Powered Health: Unlocking the Possibility of You."
"Technology gives us the power to digitize, decentralize and
democratize healthcare, create a shared language between you and
your doctor – and put more control of your health in your hands,"
Mr. Ford said. "We're creating a future that will bring you and
your loved ones care that's more personal and precise. It's
happening right now. And its potential is no less than
Lingo – Speaking Your Body's Unique Language
During the keynote, the company announced it's developing a new
category of consumer biowearables called Lingoi. These
biowearables are being designed to translate your body's unique
language into actionable data to help you track and measure your
general health and wellness. The sensor technology is being
designed to track key signals in the body such as glucose, ketones
and lactate, and could also be used one day to track alcohol
"This will be like having a window into your body," Mr. Ford
said. "It's science that you will be able to access any time so you
can understand what your body is telling you and what it needs. Our
vision is that Lingo will go far beyond today's wearables for
consumers to help you proactively manage your health, nutrition and
Lingo extends the Abbott
sensing technology platform that Abbott pioneered in 2014 for people with
diabetes, allowing people to continuously monitor their glucose
levels with a small sensor on the back of the upper arm. Actress
and comedian Sherri Shepherd shared
live on the CES stage how FreeStyle Libre 2 changed her life,
giving her glucose readings, right on her smartphoneii,
unique to her body so she can make healthier decisions.
Abbott then built this
technology platform to develop a product designed for athletes with
the 2020 launch of Libre Sense Glucose Sport
Biowearableiii in Europe. Elite athletes, like marathon world
record holder Eliud Kipchoge, use this biowearable to optimize how
they fuel their bodies for rigorous training. Lingo aims to expand
glucose monitoring to people looking to manage their weight, sleep
better, improve energy and think clearer.
Abbott is designing Lingo to
measure other biomarkers beyond glucose in the future. A ketone
biowearable is being developed to track ketones continuously, see
how fast you are getting into ketosis, and understand exactly what
keeps you there by providing insights on dieting and weight loss. A
lactate biowearable is in development to track continuous lactate
build up during exercise, which can be used as an indicator of
A Human Focus
Beyond those who demonstrated the human impact of Abbott's sensors, Mr. Ford was joined on stage
by people whose lives were impacted by Abbott devices, partners who rallied to
provide seamless and safe travel experiences and other visionaries
in the industry.
- Tyrone Morris, a heart failure
patient who was given six months to live, shared his story of how
he beat the odds thanks to three separate Abbott devices: HeartMate 3iv,
CardioMEMSv and an implantable defibrillator. Today,
Morris owns a barbecue catering business and food trucks in
Humble, Texas, where he
specializes in low-sodium recipes.
- United Airlines' Managing Director of Hospitality &
Planning Aaron McMillan and Dr.
Patrice Harris, co-founder and CEO
of eMed, a digital health company democratizing healthcare through
its Digital-Point-of-Care™ platform, described how they came
together with Abbott to help
people fly confidently and conveniently with BinaxNOW COVID-19 Home
Testsvi. United customers can take the proctored tests
when traveling and have those results seamlessly confirmed by
Abbott's NAVICA app and verified
through United's Travel Ready Center.
- Dr. Fiona Gupta of Mount Sinai
Health System in New York
highlighted how she uses the NeuroSphere Virtual Clinic, a
first-of-its-kind technology in the U.S., that provides people with
deep brain stimulation remotely, so physicians can optimize and
adjust treatments over cellular or Wi-Fi while Parkinson's and
chronic pain patients consult with them from the comfort of their
- The head of the University of Southern
California's Center for Body Computing Dr. Leslie Saxon shared her vision of "Lifecare,"
which addresses everything from preventing sudden deaths to
enhancing human performance.
- Dr. Mary Rodgers, an
Abbott virus hunter, shared how a
first-of-its-kind network called the Abbott Pandemic Defense
Coalition – stretching from Brazil
to Senegal to Thailand – is working to identify new viruses
and help stop them before they can spread.
- Dr. Hakim Bouzamondo, head of Nutrition research and
development at Abbott, shared how
the science behind the microbiome can optimize overall health with
Indications and Important Safety Information
FreeStyle Libre 2 system: Failure to use FreeStyle Libre 2 system
as instructed in labeling may result in missing a severe low or
high glucose event and/or making a treatment decision, resulting in
injury. If glucose alarms and readings do not match symptoms or
expectations, use a fingerstick value from a blood glucose meter
for treatment decisions. Seek medical attention when appropriate or
contact Abbott at 855-632-8658 or
FreeStyleLibre.us for safety info.
Abbott is a global healthcare
leader that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
109,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn
at www.linkedin.com/company/abbott-/, on Facebook
at www.facebook.com/Abbott and on Twitter
i The Lingo portfolio of products are under
development and are not intended for medical use. They are not
intended for use in screening, diagnosis, treatment, cure,
mitigation, prevention, or monitoring of diseases. Lingo Portfolio
of products are not for sale in the U.S.
ii The FreeStyle Libre 2 app is only compatible
with certain mobile devices and operating systems. Please check our
website for more information about device compatibility before
using the app. Use of the FreeStyle Libre 2 app requires
registration with LibreView.
iii The Libre Sense Biosensor is not available
in the United States and not
intended for medical use.
iv The HeartMate 3 Left Ventricular Assist
System is indicated for providing short- and long-term mechanical
circulatory support in adult and pediatric patients with advanced
refractory left ventricular heart failure and with an appropriate
body surface area. Prior to using this device, please review the
Instructions for Use at https://www.cardiovascular.abbott/us. Views
expressed are the patient's own.
v The CardioMEMS™ HF System is indicated
for wirelessly measuring and monitoring pulmonary artery (PA)
pressure and heart rate in New York Heart Association (NYHA) Class
III heart failure patients who have been hospitalized for heart
failure in the previous year. The hemodynamic data are used by
physicians for heart failure management and with the goal of
reducing heart failure hospitalizations. Prior to using this
device, please review the Instructions for Use at
https://www.cardiovascular.abbott/us. Views expressed are the
vi The BinaxNOW™ COVID-19 Ag Card Home Test has received U.S. Food and
Drug Administration (FDA) Emergency Use Authorization (EUA). This
product has not been FDA cleared or approved but has been
authorized by FDA under an EUA. This product has been authorized
only for the detection of proteins from SARS-CoV-2, not for any
other viruses or pathogens. This product is only authorized for the
duration of the declaration that circumstances exist justifying the
authorization of emergency use of IVDs for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked sooner.